Cargando…
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791065/ https://www.ncbi.nlm.nih.gov/pubmed/33414394 http://dx.doi.org/10.1038/s41408-020-00392-1 |
| _version_ | 1783633532593111040 |
|---|---|
| author | Palandri, Francesca Palumbo, Giuseppe Alberto Elli, Elena Maria Polverelli, Nicola Benevolo, Giulia Martino, Bruno Abruzzese, Elisabetta Tiribelli, Mario Tieghi, Alessia Latagliata, Roberto Cavazzini, Francesco Bergamaschi, Micaela Binotto, Gianni Crugnola, Monica Isidori, Alessandro Caocci, Giovanni Heidel, Florian Pugliese, Novella Bosi, Costanza Bartoletti, Daniela Auteri, Giuseppe Cattaneo, Daniele Scaffidi, Luigi Trawinska, Malgorzata Monica Stella, Rossella Ciantia, Fiorella Pane, Fabrizio Cuneo, Antonio Krampera, Mauro Semenzato, Gianpietro Lemoli, Roberto Massimo Iurlo, Alessandra Vianelli, Nicola Cavo, Michele Breccia, Massimo Bonifacio, Massimiliano |
| author_facet | Palandri, Francesca Palumbo, Giuseppe Alberto Elli, Elena Maria Polverelli, Nicola Benevolo, Giulia Martino, Bruno Abruzzese, Elisabetta Tiribelli, Mario Tieghi, Alessia Latagliata, Roberto Cavazzini, Francesco Bergamaschi, Micaela Binotto, Gianni Crugnola, Monica Isidori, Alessandro Caocci, Giovanni Heidel, Florian Pugliese, Novella Bosi, Costanza Bartoletti, Daniela Auteri, Giuseppe Cattaneo, Daniele Scaffidi, Luigi Trawinska, Malgorzata Monica Stella, Rossella Ciantia, Fiorella Pane, Fabrizio Cuneo, Antonio Krampera, Mauro Semenzato, Gianpietro Lemoli, Roberto Massimo Iurlo, Alessandra Vianelli, Nicola Cavo, Michele Breccia, Massimo Bonifacio, Massimiliano |
| author_sort | Palandri, Francesca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7791065 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77910652021-01-15 Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis Palandri, Francesca Palumbo, Giuseppe Alberto Elli, Elena Maria Polverelli, Nicola Benevolo, Giulia Martino, Bruno Abruzzese, Elisabetta Tiribelli, Mario Tieghi, Alessia Latagliata, Roberto Cavazzini, Francesco Bergamaschi, Micaela Binotto, Gianni Crugnola, Monica Isidori, Alessandro Caocci, Giovanni Heidel, Florian Pugliese, Novella Bosi, Costanza Bartoletti, Daniela Auteri, Giuseppe Cattaneo, Daniele Scaffidi, Luigi Trawinska, Malgorzata Monica Stella, Rossella Ciantia, Fiorella Pane, Fabrizio Cuneo, Antonio Krampera, Mauro Semenzato, Gianpietro Lemoli, Roberto Massimo Iurlo, Alessandra Vianelli, Nicola Cavo, Michele Breccia, Massimo Bonifacio, Massimiliano Blood Cancer J Correspondence Nature Publishing Group UK 2021-01-07 /pmc/articles/PMC7791065/ /pubmed/33414394 http://dx.doi.org/10.1038/s41408-020-00392-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Palandri, Francesca Palumbo, Giuseppe Alberto Elli, Elena Maria Polverelli, Nicola Benevolo, Giulia Martino, Bruno Abruzzese, Elisabetta Tiribelli, Mario Tieghi, Alessia Latagliata, Roberto Cavazzini, Francesco Bergamaschi, Micaela Binotto, Gianni Crugnola, Monica Isidori, Alessandro Caocci, Giovanni Heidel, Florian Pugliese, Novella Bosi, Costanza Bartoletti, Daniela Auteri, Giuseppe Cattaneo, Daniele Scaffidi, Luigi Trawinska, Malgorzata Monica Stella, Rossella Ciantia, Fiorella Pane, Fabrizio Cuneo, Antonio Krampera, Mauro Semenzato, Gianpietro Lemoli, Roberto Massimo Iurlo, Alessandra Vianelli, Nicola Cavo, Michele Breccia, Massimo Bonifacio, Massimiliano Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_full | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_fullStr | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_full_unstemmed | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_short | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_sort | ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791065/ https://www.ncbi.nlm.nih.gov/pubmed/33414394 http://dx.doi.org/10.1038/s41408-020-00392-1 |
| work_keys_str_mv | AT palandrifrancesca ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT palumbogiuseppealberto ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT ellielenamaria ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT polverellinicola ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT benevologiulia ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT martinobruno ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT abruzzeseelisabetta ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT tiribellimario ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT tieghialessia ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT latagliataroberto ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT cavazzinifrancesco ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT bergamaschimicaela ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT binottogianni ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT crugnolamonica ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT isidorialessandro ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT caoccigiovanni ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT heidelflorian ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT pugliesenovella ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT bosicostanza ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT bartolettidaniela ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT auterigiuseppe ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT cattaneodaniele ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT scaffidiluigi ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT trawinskamalgorzatamonica ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT stellarossella ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT ciantiafiorella ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT panefabrizio ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT cuneoantonio ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT kramperamauro ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT semenzatogianpietro ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT lemolirobertomassimo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT iurloalessandra ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT vianellinicola ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT cavomichele ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT brecciamassimo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT bonifaciomassimiliano ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis |